THE ROLE OF RSV VACCINATION IN THE PREVENTION OF RESPIRATORY DISEASES IN OLDER ADULTS
DOI:
https://doi.org/10.31435/ijitss.1(49).2026.4899Keywords:
Respiratory Syncytial Virus Infections, Vaccines, Aged, Respiratory Tract InfectionsAbstract
Introduction and objective: Respiratory syncytial virus (RSV) is one of the leading causes of lower respiratory tract infections in older adults. In 2023, the first subunit vaccines based on the prefusion conformation of the RSV fusion protein - Arexvy and Abrysvo - were approved, followed in 2024 by the mRNA-1345 vaccine marketed as mRESVIA. The aim of this study is to present the importance of RSV vaccination in the prevention of respiratory diseases in adults aged ≥60 years.
Review methods: The literature review was conducted using articles available in the PubMed, EMBASE, Web of Science, and Cochrane Library databases. The analysis focused on studies addressing RSV epidemiology as well as the efficacy and safety of RSV vaccines, particularly Arexvy and Abrysvo. FDA and CDC/ACIP documents were also included. Studies involving pediatric populations and narrative reviews were excluded.
State of knowledge: RSV accounts for 5-10% of lower respiratory tract infections in older adults, with mortality among infected individuals reaching 2-5%. Arexvy induces a strong immune response, while Abrysvo is characterized by a favorable safety profile. Studies have demonstrated vaccine efficacy ranging from 66-83% against RSV-associated lower respiratory tract disease and over 90% against severe RSV infection. Protection conferred by Arexvy persists for at least two seasons.
Summary: RSV vaccination reduces the incidence of lower respiratory tract infections, hospitalizations, and mortality in the older adult population. The 2024 ACIP guidelines recommend a single dose of RSV vaccine for individuals aged ≥75 years and for adults aged 60-74 years with risk factors, without routine booster doses.
References
O'Shea, M. K., Pipkin, C., Cane, P. A., & Gray, G. C. (2007). Respiratory syncytial virus: An important cause of acute respiratory illness among young adults undergoing military training. Influenza and Other Respiratory Viruses, 1(5–6), 193–197. https://doi.org/10.1111/j.1750-2659.2007.00029.x
Hall, C. B., Long, C. E., & Schnabel, K. C. (2001). Respiratory syncytial virus infections in previously healthy working adults. Clinical Infectious Diseases, 33(6), 792–796. https://doi.org/10.1086/322657
Belongia, E. A., King, J. P., Kieke, B. A., Pluta, J., Al-Hilli, A., Meece, J. K., & Shinde, V. (2018). Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults ≥60 years old. Open Forum Infectious Diseases, 5(12), ofy316. https://doi.org/10.1093/ofid/ofy316
Falsey, A. R., & Walsh, E. E. (2000). Respiratory syncytial virus infection in adults. Clinical Microbiology Reviews, 13(3), 371–384. https://doi.org/10.1128/CMR.13.3.371
Maggi, S., Veronese, N., Burgio, M., Cammarata, G., Ciuppa, M. E., Ciriminna, S., Di Gennaro, F., Smith, L., Trott, M., Dominguez, L. J., Giammanco, G. M., De Grazia, S., Costantino, C., Vitale, F., & Barbagallo, M. (2022). Rate of hospitalizations and mortality of respiratory syncytial virus infection compared to influenza in older people: A systematic review and meta-analysis. Vaccines, 10(12), 2092. https://doi.org/10.3390/vaccines10122092
Wongsurakiat, P., Sunhapanit, S., & Muangman, N. (2023). Bacterial coinfection and superinfection in respiratory syncytial virus-associated acute respiratory illness: Prevalence, pathogens, initial antibiotic-prescribing patterns and outcomes. Tropical Medicine and Infectious Disease, 8(3), 148. https://doi.org/10.3390/tropicalmed8030148
Ackerson, B., Tseng, H. F., Sy, L. S., Solano, Z., Slezak, J., Luo, Y., Fischetti, C. A., & Shinde, V. (2019). Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clinical Infectious Diseases, 69(2), 197–203. https://doi.org/10.1093/cid/ciy991
World Health Organization. (2025). Respiratory syncytial virus (RSV): Fact sheet. WHO Newsroom. http://www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-(rsv)
Walsh, E. E., Pérez Marc, G., Zareba, A. M., et al. (2023). Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. The New England Journal of Medicine, 388(16), 1465–1477. https://doi.org/10.1056/NEJMoa2213836
Papi, A., Ison, M. G., Langley, J. M., Lee, D. G., Leroux-Roels, I., Martinon-Torres, F., Schwarz, T. F., van Zyl-Smit, R. N., Campora, L., Dezutter, N., de Schrevel, N., Fissette, L., David, M. P., Van der Wielen, M., Kostanyan, L., Hulstrøm, V., & AReSVi-006 Study Group. (2023). Respiratory syncytial virus prefusion F protein vaccine in older adults. The New England Journal of Medicine, 388(7), 595–608. https://doi.org/10.1056/NEJMoa2209604
Britton, A., Roper, L. E., Kotton, C. N., Hutton, D. W., Fleming-Dutra, K. E., Godfrey, M., Ortega-Sanchez, I. R., Broder, K. R., Talbot, H. K., Long, S. S., Havers, F. P., & Melgar, M. (2024). Use of respiratory syncytial virus vaccines in adults aged ≥60 years: Updated recommendations of the Advisory Committee on Immunization Practices—United States, 2024. MMWR. Morbidity and Mortality Weekly Report, 73(32), 696–702. https://doi.org/10.15585/mmwr.mm7332e1
Falsey, A. R., & Walsh, E. E. (2005). Respiratory syncytial virus infection in elderly adults. Drugs & Aging, 22(7), 577–587. https://doi.org/10.2165/00002512-200522070-00004
Surie, D., Yuengling, K. A., DeCuir, J., Zhu, Y., Gaglani, M., Ginde, A. A., Talbot, H. K., Casey, J. D., Mohr, N. M., Ghamande, S., Gibbs, K. W., Files, D. C., Hager, D. N., Ali, H., Prekker, M. E., Gong, M. N., Mohamed, A., Johnson, N. J., Steingrub, J. S., Peltan, I. D., … IVY Network. (2023). Disease severity of respiratory syncytial virus compared with COVID-19 and influenza among hospitalized adults aged ≥60 years—IVY Network, 20 U.S. states, February 2022–May 2023. MMWR. Morbidity and Mortality Weekly Report, 72(40), 1083–1088. https://doi.org/10.15585/mmwr.mm7240a2
Surie, D., Self, W. H., Zhu, Y., Yuengling, K. A., Johnson, C. A., Grijalva, C. G., Dawood, F. S., & Investigating Respiratory Viruses in the Acutely Ill (IVY) Network. (2024). RSV vaccine effectiveness against hospitalization among US adults 60 years and older. JAMA, 332(13), 1105–1107. https://doi.org/10.1001/jama.2024.15775
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., Zhou, T., Graepel, K. W., Kumar, A., Moin, S., Boyington, J. C., Chuang, G. Y., Soto, C., Baxa, U., Bakker, A. Q., Spits, H., … Kwong, P. D. (2013). Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science, 342(6158), 592–598. https://doi.org/10.1126/science.1243283
Ison, M. G., Papi, A., Athan, E., Feldman, R. G., Langley, J. M., Lee, D. G., Leroux-Roels, I., Martinon-Torres, F., Schwarz, T. F., van Zyl-Smit, R. N., Verheust, C., Dezutter, N., Gruselle, O., Fissette, L., David, M. P., Kostanyan, L., Hulstrøm, V., Olivier, A., Van der Wielen, M., Descamps, D., … AReSVi-006 Study Group. (2024). Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clinical Infectious Diseases, 78(6), 1732–1744. https://doi.org/10.1093/cid/ciae010
GlaxoSmithKline. (2024). Arexvy: Summary of product characteristics. https://ec.europa.eu/health/documents/community-register/2023/20230606159374/anx_159374_pl.pdf
Pfizer Europe MA EEIG. (2023). Abrysvo: Summary of product characteristics. https://ec.europa.eu/health/documents/community-register/2023/20230823160227/anx_160227_pl.pdf
Moderna Biotech Spain, S.L. (2024). mRESVIA: Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/mresvia-epar-product-information_en.pdf
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Katarzyn Karaś, Sylwia Mroszczyk, Dawid Nowicki, Małgorzata Muszyńska, Paulina Małyszczak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
